Literature DB >> 3117534

Clinical consequences of development of resistance to third generation cephalosporins.

F Follath1, E Costa, A Thommen, R Frei, A Burdeska, J Meyer.   

Abstract

Eighteen patients are described in whom initially sensitive microorganisms were replaced by resistant isolates during administration of ceftriaxone (n = 8), cefoperazone (n = 5), moxalactam (n = 4), cefotaxime (n = 2) or ceftazidime (n = 1), despite combination with aminoglycosides. All patients had documented gram-negative infections; in 12 patients underlying haematological diseases were present. Resistant strains of Enterobacter cloacae (14), Serratia marcescens (4), Klebsiella oxytoca (3), Pseudomonas aeruginosa (2) and Citrobacter freundii (2) emerged within 2 to 19 (mean 9) days after the beginning of treatment. In 12 patients relapse or secondary infections occurred. Seven of the patients with haematological disorders died. Resistance development was seen in 8 of 29 patients on ceftriaxone and 4 of 10 patients on moxalactam during prospective evaluations; the other drugs were used sporadically. Thus, selection of resistant bacteria is relatively frequent and may have serious clinical consequences in patients with impaired host-defense mechanisms.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3117534     DOI: 10.1007/bf02013108

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  17 in total

1.  Evaluation of antibiotic usage: a comprehensive look at alternative approaches.

Authors:  C M Kunin
Journal:  Rev Infect Dis       Date:  1981 Jul-Aug

2.  Prophylactic parenteral cephalosporins in surgery. Are the newer agents better?

Authors:  J T DiPiro; T A Bowden; V H Hooks
Journal:  JAMA       Date:  1984-12-21       Impact factor: 56.272

Review 3.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

4.  [Monotherapy of systematic Pseudomonas aeruginosa infections with ceftazidime. The causes of therapeutic failures].

Authors:  J Blaser; A Bauernfeind; M Vogt; R Lüthy
Journal:  Dtsch Med Wochenschr       Date:  1983-09-02       Impact factor: 0.628

5.  Influence of third-generation cephalosporins on aerobic intestinal flora.

Authors:  J P Guggenbichler; J Kofler
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

6.  Resistance caused by decreased penetration of beta-lactam antibiotics into Enterobacter cloacae.

Authors:  K Bush; S K Tanaka; D P Bonner; R B Sykes
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

7.  Ceftazidime in severe infections: a Swiss multicentre study.

Authors:  P Francioli; M Clément; S Geroulanos; A von Graevenitz; R Luthy; C Regamey; H Stalder; M Vogt; F A Waldvogel
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

8.  Use of cefotaxime, a beta-lactamase stable cephalosporin, in the therapy of serious infections, including those due to multiresistant organisms.

Authors:  E L Francke; H C Neu
Journal:  Am J Med       Date:  1981-09       Impact factor: 4.965

9.  Emergence of resistance to beta-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections.

Authors:  L C Preheim; R G Penn; C C Sanders; R V Goering; D K Giger
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

10.  Moxalactam therapy for bacterial infections.

Authors:  D J Winston; R W Busuttil; T O Kurtz; L S Young
Journal:  Arch Intern Med       Date:  1981-11
View more
  11 in total

Review 1.  Drug treatment of pneumonia in the hospital. What are the choices?

Authors:  M Aoun; J Klastersky
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

2.  Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins.

Authors:  J C Fung-Tomc; E Gradelski; E Huczko; T J Dougherty; R E Kessler; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

3.  Susceptibility of stably derepressed beta-lactamase producing strains to imipenem and four quinolones.

Authors:  R N Jones; A L Barry
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-02       Impact factor: 3.267

Review 4.  Clinical importance of inducible beta-lactamases in gram-negative bacteria.

Authors:  C C Sanders; W E Sanders
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

5.  Septicaemia caused by an Enterobacter cloacae strain varying in resistance against cephalosporins.

Authors:  B M Andersen; I M Dahl; R C George; A Gilfillian
Journal:  Infection       Date:  1989 May-Jun       Impact factor: 3.553

Review 6.  Beta-lactamases: current situation and clinical importance.

Authors:  J Garau
Journal:  Intensive Care Med       Date:  1994-07       Impact factor: 17.440

7.  Epidemiological risk factors for isolation of ceftriaxone-resistant versus -susceptible citrobacter freundii in hospitalized patients.

Authors:  Peter W Kim; Anthony D Harris; Mary-Claire Roghmann; J Glenn Morris; Arjun Strinivasan; Eli N Perencevich
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

8.  The kinetics of non-stoichiometric bursts of beta-lactam hydrolysis catalysed by class C beta-lactamases.

Authors:  M G Page
Journal:  Biochem J       Date:  1993-10-01       Impact factor: 3.857

9.  Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels.

Authors:  J Fung-Tomc; T J Dougherty; F J DeOrio; V Simich-Jacobson; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

10.  A selection cartridge for rapid detection and analysis of spontaneous mutations including insertions of transposable elements in Enterobacteriaceae.

Authors:  T Raabe; E Jenny; J Meyer
Journal:  Mol Gen Genet       Date:  1988-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.